Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Dermata Therapeutics (DRMA – Research Report) yesterday and set a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Anthony Vendetti has given his Buy rating due to a combination of factors including the promising results from Dermata Therapeutics’ Phase 3 trial of their acne treatment, Xyngari. The trial met all primary endpoints, showing a statistically significant improvement in acne symptoms compared to a placebo, which underscores the treatment’s efficacy and potential regulatory success.
Additionally, the once-weekly application of Xyngari offers a significant advantage over existing treatments that require daily use, potentially improving patient compliance. Despite being a pre-revenue company, Dermata’s financial position, with recent fundraising efforts, supports its ongoing development plans. The company’s innovative technology and the potential for partnerships or licensing agreements further bolster confidence in its future prospects, justifying the Buy rating.